Notice of Annual General Meeting of Shareholders
13 mai 2021 11h45 HE
|
Kiadis Pharma Netherlands B.V.
Amsterdam, The Netherlands, 13 May 2021 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that...
Final results of the Offer for Kiadis: 97.39% of Kiadis Shares in total committed under the Offer
29 avr. 2021 01h00 HE
|
Kiadis Pharma Netherlands B.V.
This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Article 17 paragraph 4 of the...
Delisting of Kiadis will be effective on 25 May 2021
26 avr. 2021 12h00 HE
|
Kiadis Pharma Netherlands B.V.
This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”) in connection with the recommended public offer by the Offeror...
Sanofi completes Kiadis acquisition
16 avr. 2021 12h00 HE
|
Kiadis Pharma Netherlands B.V.
This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”) in connection with the public offer by the Offeror for all the...
Sanofi declares the Offer for Kiadis unconditional
13 avr. 2021 01h00 HE
|
Kiadis Pharma Netherlands B.V.
This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Article 16, paragraph 1 and 2...
Kiadis employee options committed under the Sanofi Offer
09 avr. 2021 01h00 HE
|
Kiadis Pharma Netherlands B.V.
This is a press release by Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Section 5 paragraphs 4 and 5 of the Dutch Decree on Public Takeover Bids (Besluit openbare biedingen Wft) (the...
Kiadis Pharma announces annual results for the year ended December 31, 2020
07 avr. 2021 11h45 HE
|
Kiadis Pharma Netherlands B.V.
New strategic focus results in significant progress in cell based therapies Amsterdam, The Netherlands, April 7, 2021 – Kiadis Pharma N.V. (“Kiadis”,...
Kiadis EGM adopts all resolutions related to the recommended public offer by Sanofi
30 mars 2021 07h48 HE
|
Kiadis Pharma Netherlands B.V.
This is a press release by Kiadis Pharma N.V. (“Kiadis”) in connection with the public offer by Sanofi Foreign Participations B.V. (“the Offeror”), a wholly owned subsidiary of Sanofi (“Sanofi”), for...
Kiadis issues shares to Kreos Capital following agreed conversion of convertible bonds
15 févr. 2021 11h45 HE
|
Kiadis Pharma Netherlands B.V.
This is a press release by Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Section 5 paragraphs 4 and 5 and Section 6 paragraph 2 of the Dutch Decree on Public Takeover Bids (Besluit...
Sanofi launches recommended cash offer for all shares in Kiadis
12 févr. 2021 01h00 HE
|
Kiadis Pharma Netherlands B.V.
This is a joint press release by Sanofi Foreign Participations B.V. (the “Offeror”), Sanofi (“Sanofi”) and Kiadis Pharma N.V. (“Kiadis”), pursuant to the provisions of Article 4 paragraph 1, Article...